Cellular immunotherapy licensed for advanced prostate cancer.
Traynor
Kate
K
D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D014020:Tissue Extracts / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T